Shilajit and Immunosuppressants (Ciclosporin, Tacrolimus, Sirolimus, Mycophenolate)

Shilajit is a traditional resin from high mountain regions that is rich in fulvic acids and dibenzo-α-pyrones and is gaining popularity worldwide as a food supplement. Immunosuppressants such as ciclosporin, tacrolimus, sirolimus and mycophenolate are essential medicines used to help prevent rejection reactions after organ transplantation or in certain autoimmune conditions. This article considers how Shilajit might influence the immune system and the pharmacokinetics of these medicines, discusses potential risks and gives practical, risk‑aware guidance.

Background information on Shilajit can be found in our articles Shilajit: effects and Shilajit: interactions.

Mechanism of possible interaction

Pharmacodynamic: In particular, the fulvic acids contained in Shilajit are discussed in the literature in relation to immunomodulatory effects. In vitro, complement‑modulating properties and effects on macrophage and lymphocyte functions have been described. Such potentially immune‑stimulating or immune‑regulating actions could in theory counteract the intended immunosuppression – a particular concern for transplant recipients. (1)

Pharmacokinetic: The calcineurin inhibitors tacrolimus and ciclosporin and the mTOR inhibitor sirolimus are substrates of CYP3A4 and the efflux transporter P‑glycoprotein (P‑gp) and have a narrow therapeutic window. Numerous herbal products can inhibit or induce CYP3A4/P‑gp and in this way significantly raise or lower blood levels. There are currently no robust human data for Shilajit in this regard; however, based on general mechanisms, extra caution is advisable. (2)(3)(4)

Clinical evidence

No direct clinical studies or case reports on Shilajit in combination with ciclosporin, tacrolimus, sirolimus or mycophenolate have been published to date. However, experience with other herbal preparations, such as St John’s wort, illustrates how significant interactions can be: in transplant recipients, CYP3A4/P‑gp induction and the resulting markedly reduced immunosuppressant levels have been associated with rejection episodes. This evidence highlights the importance of particular caution with non‑standardised plant‑based products in people receiving immunosuppressive therapy. (6)(2)

For sirolimus there is also good evidence that inhibitors of the CYP3A4/P‑gp pathway can substantially increase blood levels; therefore there are strict warnings regarding grapefruit, azole antifungals and other inhibitors. (3)

Risk assessment

Severity: High. Even small fluctuations in immunosuppressant levels can be associated with toxicity (e.g. nephrotoxicity) or insufficient immunosuppression. (2)(3)(4)

Likelihood: Unknown due to a lack of direct data; however, the possibility is mechanistically plausible (immunomodulation; potential influence on CYP3A4/P‑gp by plant‑derived components). For this reason, a precautionary avoidance of Shilajit during treatment with immunosuppressants is generally advisable. (1)(2)(3)

Product quality: Independently of interactions, Shilajit products have in some cases been found to contain heavy metals (e.g. lead, arsenic, cadmium), which may be of particular concern where organs such as the kidneys or liver are already under strain. Systematic reviews report variable, sometimes above‑limit levels and advise against use without verified quality control. (5) More on this in Shilajit: side effects.

Shilajit Capsules

✓ High-quality, natural Shilajit from the Himalayas

✓ With 50% fulvic acid & 12% humic acid

✓ 500 mg Shilajit extract per capsule

✓ Extract ratio 50:1 (equivalent to 25,000 mg Shilajit resin per capsule)

£18.00

ADD TO BASKET

View product

Practical recommendations

1. Transplant recipients and people on immunosuppressive therapy: It is generally advisable to avoid Shilajit while you are taking ciclosporin, tacrolimus, sirolimus or mycophenolate. Always discuss any food supplement in advance with your transplant team or specialist centre. (6)(4)
2. If you are still considering Shilajit:
   • Always seek prior medical advice from your doctor; keep a record of start/stop dates and dosage.
   • Therapeutic drug monitoring (TDM): short‑term, close monitoring of trough levels (particularly tacrolimus, ciclosporin, sirolimus), alongside clinical monitoring for signs suggestive of toxicity or under‑immunosuppression. (2)(3)
   • No “dose‑timing trick”: Taking the products at different times of day (e.g. morning/evening) is not a reliable way to address potential pharmacodynamic risks related to immunomodulation.
   • Quality/analytics: Without certified heavy‑metal testing reports and standardisation, use is generally not recommended. (5)
3. Respect known “red lines”: Also avoid grapefruit/pomelo/pomegranate and other strong CYP3A4/P‑gp modulators if your transplant centre advises this. (2)(3)(4)
4. Alternatives: For fatigue or support with recovery, focus instead on gradual physical activity, good sleep hygiene, and individual optimisation of protein and micronutrient intake; evidence‑based supplements should only be used after medical review.

Background on individual immunosuppressants

Tacrolimus (CNI): Substrate of CYP3A4 and P‑gp; narrow therapeutic window; numerous CYP3A4/P‑gp‑related interactions with herbal products have been described. (2)

Ciclosporin (CNI): Also a CYP3A4/P‑gp substrate; interactions with inhibitors/inducers can markedly alter blood levels; strict TDM is required. (4)

Sirolimus (mTOR inhibitor): Strongly dependent on CYP3A4/P‑gp; known interactions with inhibitors/inducers; clinically relevant dose adjustments may be needed. (3)

Mycophenolate: Has antiproliferative effects; interactions are less related to CYP3A4, but any additional intolerance/diarrhoea or supplement use without evidence can increase overall risk. Always discuss changes with your specialist centre. (4)

Conclusion

There are no direct clinical data on Shilajit in combination with ciclosporin, tacrolimus, sirolimus or mycophenolate. However, the available mechanistic and indirect evidence suggests that the potential risk is significant and avoidable. People receiving immunosuppressive therapy – especially after transplantation – are generally advised to avoid Shilajit. If its use is nevertheless being considered, this should only take place following an individual medical benefit‑risk assessment, with close TDM and using carefully quality‑checked products.

Medical disclaimer

Important note: This information does not replace professional medical advice. Before taking Shilajit together with [medicine], always consult your doctor or pharmacist. Each individual may react differently to food supplements and medicines.